Pharma major Lupin can now market a generic version of Tamiflu capsules after it got approval from the US Food and Drug Administration (USFDA) to do so, it was revealed in an announcement recently.
Tamilflu capsules are used to treat the viral disease flu (influenza).
In a statement Lupin stated it got final approval from USFDA to market oseltamivir phosphate capsules, a generic version of Hoffman-La Roche Inc’s Tamiflu capsules in strengths of 30 mg, 45 mg, and 75 mg.
Oseltamivir Phosphate Capsules USP, 30 mg, 45 mg, and 75 mg recorded annual sales of approximately USD 467.8 million in the US market, as per IMS MAT October 2017 data.
Lupin deals in wide range of branded and generic formulations and biotechnology products. The company holds global leadership position in the Anti-TB segment.